[Form 4] NewAmsterdam Pharma Co N.V. Insider Trading Activity
Rhea-AI Filing Summary
NewAmsterdam Pharma Co N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported stock option exercises and related share sales. On January 20 and 21, 2026, he exercised options to acquire 60,216 and 39,784 ordinary shares at an exercise price of $9.26 per share. On the same dates, he sold several blocks of ordinary shares, including 39,712, 19,604, and 24,362 shares at prices referenced in ranges from about $30.17 to $34.31 per share, as detailed in the footnotes.
After these transactions, Somaiya directly held 58,382 ordinary shares and 662,814 option-based derivative securities. The filing states that at least one sale transaction was carried out under a Rule 10b5-1 trading plan, and notes that the underlying option was granted on November 1, 2023 with vesting over four years, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (Right to Buy) | 39,784 | $0.00 | -- |
| Exercise | Ordinary Shares | 39,784 | $9.26 | $368K |
| Sale | Ordinary Shares | 15,422 | $33.25 | $513K |
| Sale | Ordinary Shares | 24,362 | $33.80 | $823K |
| Exercise | Option (Right to Buy) | 60,216 | $0.00 | -- |
| Exercise | Ordinary Shares | 60,216 | $9.26 | $558K |
| Sale | Ordinary Shares | 900 | $30.64 | $28K |
| Sale | Ordinary Shares | 39,712 | $31.78 | $1.26M |
| Sale | Ordinary Shares | 19,604 | $32.38 | $635K |
Footnotes (1)
- This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
